Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury

Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury
Neuren Pharmaceuticals chief executive Jon Pilcher says the Kiwi firm is in a privileged position. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
Neuren Pharmaceuticals' boss Jon Pilcher says he was punching the air after leaving a recent successful meeting with the US Food and Drug Administration.Neuren, a local company which develops treatments for neurological disorders including Rett syndrome, has been cleared to begin phase-three trials for the drug NNZ-2591 to treat Phelan-McDermid syndrome. It will be the first-ever phase-three trial in children with the rare genetic condition.The disorders Neuren targets for treatment with its drugs are often debilitating and can ha...

More Markets

Locate Technologies posts quarterly loss ahead of NZX listing move
Markets

Locate Technologies posts quarterly loss ahead of NZX listing move

Locate will be providing New Zealand’s first listed bitcoin treasury.

An updated recap: Fonterra’s $4.2b Mainland sale
Primary Sector

An updated recap: Fonterra’s $4.2b Mainland sale

Today's the day the sale will get the blessing of farmers.

The ‘Aussie Premium’ baked into NZX stocks
Opinion

Brian Robins: The ‘Aussie Premium’ baked into NZX stocks

New Zealand entities launching in Australia have clear benefits.